Analytical Data
-
基因名
MTX1
- Application
-
别名
MTX1；MTX；MTXN；Metaxin-1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q13505
-
表达区间
170-295aa
-
氨基酸序列
LDSLAVLTYARFTGAPLKVHKISNPWQSPSGTLPALRTSHGEVISVPHKIITHLRKEKYNADYDLSARQGADTLAFMSLLEEKLLPVLVHTFWIDTKNYVEVTRKWYAEAMPFPLNFFLPGRMQRQ
-
分子量
15.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MTX1 (Methotrexate Resistance Protein 1) is a member of the ATP-binding cassette (ABC) transporter family and has garnered attention for its role in drug resistance, particularly in cancer therapy. Research has shown that MTX1 can contribute to the efflux of chemotherapeutic agents, thereby reducing their efficacy and facilitating tumor growth. Understanding the molecular mechanisms underlying MTX1 expression and function is crucial for improving therapeutic strategies against resistant tumors. Recent studies have focused on characterizing the MTX1 recombinant protein to elucidate its structural and functional properties. This includes examining its binding affinities, transport capabilities, and interactions with various substrates. By producing and analyzing MTX1 recombinant proteins in controlled laboratory settings, researchers aim to develop inhibitors that can effectively block its activity, potentially overcoming drug resistance in cancer treatments. Additionally, insights gained from MTX1 studies may also extend to other ABC transporters, offering a broader understanding of how similar mechanisms contribute to multidrug resistance in various diseases. This research not only highlights the importance of MTX1 in therapeutic contexts but also emphasizes the necessity for innovative approaches to tackle drug resistance in clinical settings.
